Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion type Assertion NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_head.
- NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion description "[We used ALK fusion-positive and -negative lung cancer cell lines; crizotinib, PHA-665752, and saracatinib, and stable transfection with shMET.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_provenance.
- NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion evidence source_evidence_literature NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_provenance.
- NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion SIO_000772 24490607 NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_provenance.
- NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion wasDerivedFrom befree-20150227 NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_provenance.
- NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_assertion wasGeneratedBy ECO_0000203 NP235717.RAMFp_Z_irxVwguPTNdrwujW1uooB3Q_hWe92vKw2pfJU130_provenance.